Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
PONTE VEDRA, Fla., July 17, 2024 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes,